The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo
Cancer Research and Treatment. 2016;48(2):687-697 
Suppression of autophagy sensitizes multidrug resistant cells towards Src tyrosine kinase specific inhibitor PP2
Cancer Letters. 2011;310(2):188-197
Apoptotic effect of PP2 a Src tyrosine kinase inhibitor, in murine B cell leukemia
Journal of Cellular Biochemistry. 2004;93(3):629-638
Development of a novel bone-targeted Src tyrosine kinase inhibitor AP23451 having potent in vitro
and in vivo
anti-tesorptive properties
European Journal of Haematology. 2003;70(4):271-271
BMS-536924, an ATP-competitive IGF-1R/IR inhibitor, decreases viability and migration of temozolomide-resistant glioma cells in vitro and suppresses tumor growth in vivo
OncoTargets and Therapy. 2015;689
Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2
Biochemical and Biophysical Research Communications. 2006;350(2):450-456
Knockout of ATG5 leads to malignant cell transformation and resistance to Src family kinase inhibitor PP2
Journal of Cellular Physiology. 2017;233(1):506-515
596 POSTER The topoisomerase I inhibitor gimatecan exhibits synergistic activity with temozolomide and tyrosine kinase inhibitors in malignant glioma xenografts
European Journal of Cancer Supplements. 2008;6(12):186-187
510 Inhibition of STAT3 enhances the radiosensitising effect of temozolomide in malignant glioma cells in vitro and in vivo
European Journal of Cancer. 2014;50:166
Temozolomide in malignant glioma
OncoTargets and Therapy. 2010;139